Trial Profile
A Retrospective study to evaluate the safety, efficacy and the resistance patterns to Osimertinib treatment in patients T790M+ with Non-small cell-lung-cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer